The ESR1-mutated metastatic breast cancer market is projected to grow rapidly at a 9.6% CAGR from 2026 to 2036, driven by rising cases of endocrine-resistant HR-positive/HER2-negative breast cancer and advances in precision oncology. Novel therapies like Giredestrant, Camizestrant, and VEPPANU, the first FDA-approved PROTAC therapy, are reshaping treatment options and expanding market opportunities. The US leads the market, with about 40% of advanced breast cancer patients developing ESR1 mutations during first-line therapy, which reduces treatment effectiveness. Emerging drugs are expected to transform the treatment landscape and improve patient outcomes in the coming decade.
The myasthenia gravis market, valued at around $6 billion in 2025, is projected to grow at a 9.1% CAGR to surpass $16 billion by 2036. Growth is fueled by increasing diagnosed cases, especially among older populations, and a surge in innovative targe...
Compugen reported progress in its cancer immunotherapy programs, including active patient enrollment in the COM701 MAIA-ovarian trial with an interim analysis expected by Q1 2027. Partner AstraZeneca is advancing rilvegostomig through 11 Phase 3 tria...
AstraZeneca has received US approval for Baxfendy, the first new blood pressure drug class in over 20 years, which effectively lowers high blood pressure by blocking aldosterone production. This drug addresses a significant need as many patients stru...
